ReviewJACC. Advances2024
Device Closure of Hemodynamically Significant Patent Ductus Arteriosus in Premature Infants.
Review in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Two-Year Outcomes of a Randomized Controlled Trial of Nonintervention Versus Oral Ibuprofen for Patent Ductus Arteriosus in Premature Infants.Journal of Korean medical science · 2026Trial
- Immediate Zero-Contrast Ductal Closure Following Emergent Valvotomy in Pulmonary Atresia With Intact Ventricular Septum.JACC. Case reports · 2026Article
- Optimal timing for transcatheter device occlusion of a hemodynamically significant patent ductus arteriosus in preterm infants: evidence, uncertainty, and future directions.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Safety and Effectiveness of the KA Micro Plug for Treatment of Patent Ductus Arteriosus in Preterm Low-Birth-Weight Infants: Retrospective Analysis From a Multicenter Registry.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Percutaneous Interventions for Heart Failure in Congenital Heart Disease.Current cardiology reports · 2026Review
- Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience.Journal of the American Heart Association · 2025Article
- Piccolo Device for Treating Patent Ductus Arteriosus Beyond Premature Newborn Patients, a Novel Experience in South America: A Retrospective Study.Health science reports · 2025Article
- Fate of mitral regurgitation after transcatheter closure of patent ductus arteriosus: single centre study.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The patent ductus arteriosus is a very common condition in preterm infants, and a hemodynamically significant patent ductus arteriosus increases morbidity and mortality in these vulnerable patients. However, despite numerous randomized controlled trials, there is no consensus regarding management. Medical therapy is typically offered as first-line treatment, although it yields limited success and carries the potential for severe adverse events. In recent years, there has been rapid development in transcatheter patent ductus arteriosus closure primary with the use of the Amplatzer Piccolo Occluder, and this has gained widespread acceptance as a safe and effective alternative to surgical ligation in extremely low-birth-weight infants weighing over 700 g. This article aims to provide an appraisal of the patient selection process, a step-by-step procedural guide, and a comprehensive review of the outcomes associated with this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.